----item----
version: 1
id: {6F956D55-7B71-46BF-B81A-AE1A88376F1D}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/1995/06/26/Cortecs UK joins Exocell US to develop diabetes tests
parent: {A35CD5C5-B983-47AE-88BD-959AA5E54E36}
name: Cortecs UK joins Exocell US to develop diabetes tests
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: cd7fc74c-56a6-4cad-a4db-589548c6a917

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 405

<p>Cortecs (UK) and <strong>[C#199500031:Exocell]</strong> (US) are to link up to produce a range of point-of-care diagnostic tests for monitoring diabetes. The two companies aim to develop blood-, plasma- or serum-based kits that can measure glycated proteins in diabetes sufferers and provide an accurate result within 15 minutes at the doctor's office. Priority will be given to a rapid blood test.</p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 57

Cortecs (UK) joins Exocell (US) to develop diabetes tests
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 892

<p>Cortecs (UK) and <strong>[C#199500031:Exocell]</strong> (US) are to link up to produce a range of point-of-care diagnostic tests for monitoring diabetes. The two companies aim to develop blood-, plasma- or serum-based kits that can measure glycated proteins in diabetes sufferers and provide an accurate result within 15 minutes at the doctor's office. Priority will be given to a rapid blood test.</p><p>Under the agreement, Exocell will provide Cortecs with reagents and monoclonal antibodies already used in diabetes monitoring. Cortecs will combine these with its own Helisal range of diagnostic products. Prototypes will be developed at Cortecs' R&D facilities while Exocell will carry out laboratory and clinical tests in the US for regulatory purposes. Cortecs will manufacture the final products and select distributors. There are over 100 million diabetes sufferers worldwide.</p>
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 77

{72D49F7F-DA69-4EE0-ACAA-8D50362AD510}|{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 53

Cortecs UK joins Exocell US to develop diabetes tests
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

19950626T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

19950626T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

19950626T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT053212
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 57

Cortecs (UK) joins Exocell (US) to develop diabetes tests
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

199500031
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

255021
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T184426Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

cd7fc74c-56a6-4cad-a4db-589548c6a917
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T184426Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
